Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05820841 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Study acronym: ARCHED
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Apr 2028 to Feb 2029
    • Study completion date: Dec 2028 to Feb 2029
    v6
  2. Study sites: 11 to 17v5
  3. Study sites: 6 to 11
    • Collaborators revised (6)
    v4
  4. Study sites: 1 to 6
    • Start date changed from estimate of May 15, 2023 to Jun 7, 2023
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2023 to May 15, 2023
    • Site details revised
    • Study title shortened, about 2 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.
Trial Details
NCT Number NCT05820841
Lead Sponsor Universität des Saarlandes
Collaborators: University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital Giessen and Marburg, Saarland University Medical Center, AstraZeneca
Conditions
(from sponsor)		 Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov